Skip to content

BCAA and vitamin D administration on sarcopenia and bone metabolism abnormality in cirrhosis patients

Effects of oral BCAA and vitamin D administration on sarcopenia and bone metabolism abnormality in cirrhosis patients with hypoalbuminemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031180428
Enrollment
200
Registered
2019-03-26
Start date
2017-09-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhosis cirrhosis sarcopenia

Interventions

Sponsors

Okubo Tomomi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Decompensated cirrhosis with hypoalbuminemia

Exclusion criteria

Exclusion criteria: Patient with inborn branch chain amino acid metabolic derangement Hepatic encephalopathy more than 3 Total bilirubin value >3 mg/dl patien with decrease of the protein composition ability in the liver The patient allergic to milk The patient who has the medical history of the hyperesthesia to BCAA medicine The patient who is nursing and pregnant Patient with uncotrolled HCC or other malignant tumor Uncontrolled heart failure patient Uncontrolled hypertension or diabetes Patient with Chronic renal failure Patient of hypercalcemia Patient with hyperthyroidism Patient who already takes other vitamin D Patien who takes the drug that combination with the vitamin D preparation is contraindicated Patient with acute liver failure Patient who were judged unsuitable by test responsibility doctor

Design outcomes

Primary

MeasureTime frame
Skeletal muscle mass, grip, bone density

Secondary

MeasureTime frame
Subjective symptoms/objective symptom Performance status Mental symptom Side effect

Contacts

Public ContactTomomi Okubo

Nippon Medical Chiba Hokuso Hospital

ma6-0154@nms.ac.jp+81-476991111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026